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Abstract 
The opioid use and overdose crisis is persistent and dynamic. Opioid overdoses were initially driven in the 1990s and 
2000s by the increasing availability and misuse of prescription opioids. More recently, opioid overdoses are increas-
ing at alarming rates due to wider use of heroin, which in some places is mixed with fentanyl or fentanyl derivatives. 
Naloxone access for opioid overdose rescue is one of the US Department of Health and Human Services’ three priority 
areas for responding to the opioid crisis. This article summarizes the known benefits of naloxone access and details 
unanswered questions about overdose education and naloxone rescue kits. Hopefully future research will address 
these knowledge gaps, improve the effectiveness of opioid overdose education and naloxone distribution programs, 
and unlock the full promise of naloxone rescue kits.
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Background
As a leading cause of preventable injury and death, opioid 
overdose is a major contributor to worsening overall sur-
vival among middle-age white Americans and an increas-
ing cause of mortality among all racial and age categories 
[1]. Increases in overdose have been driven by prescrip-
tion opioids in the 1990s and 2000s and non-prescribed 
opioids in the 2000s and 2010s [2, 3]. In several commu-
nities, fentanyl has been recognized as a major contribu-
tor to increases in opioid overdose mortality since 2013 
[2, 4, 5] and fentanyl derivatives such as acetyl fentanyl, 
furanyl fentanyl and carfentanil have been detected in 
drug seizures and overdose toxicology. The US Depart-
ment of Health and Human Services has recognized opi-
oid related overdose as a major public health concern and 
acknowledged three priority areas to address this crisis: 
opioid prescriber education, community naloxone access, 
and improved access to medications for opioid use dis-
order [6]. Each of these priority areas holds promise, 
though the strength of evidence for each of these is dif-
ferent. There is substantial, strong, and reproducible 
evidence in randomized clinical trials and well-designed 
observational studies that medications for treatment 
of opioid use disorder improve mortality, reduce opioid 
use, reduce infectious risks, reduce incarceration, and 
improves birth outcomes [7]. The effectiveness of opioid 
overdose education and community naloxone distribu-
tion (OEND) in reducing overdose deaths comes from 
a smaller research set which encompasses less rigorous 
study designs including: interrupted time-series analysis, 
pre-post studies, case series, and cross sectional studies 
[8]. There is less evidence that providing education on 
safe opioid prescribing will impact opioid overdoses and 
deaths.
As access to naloxone has improved, it is clear that 
much is known about community level overdose educa-
tion and naloxone rescue distribution, but more research 
and knowledge is needed to optimize OEND as a valu-
able tool to combat the overdose crisis. This article sum-
marizes what is known and highlights areas of knowledge 
gaps with respect to opioid overdose education and 
naloxone distribution.
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What we know
Naloxone is a potent opioid antagonist that is avid at the 
mu opioid receptor. It is FDA approved for emergency 
treatment of known or suspected opioid overdose with 
respiratory and/or central nervous system depression. 
Naloxone can be administered intravenously (IV), intra-
muscularly (IM), subcutaneously (SC), and intranasally 
(IN). Naloxone has no effect in people who are not taking 
opioids. OEND programs educate laypersons to recog-
nize opioid overdose and instruct them how to adminis-
ter naloxone to reverse respiratory depression. Access to 
OEND to potential overdose bystanders through com-
munity programs has expanded to 30 states since the late 
1990s [9, 10]. Most OEND programs also provide educa-
tion about overdose prevention by instructing potential 
rescuers to recognize known risk factors for overdose 
such as: mixing opioids with other sedatives, changes 
in drug potency or purity, using high doses of prescrip-
tion opioids, and using opioids alone. Empowering peo-
ple who use opioids to engage overdose prevention by 
recognizing and addressing modifiable risk factors is an 
important feature of OEND programs. A randomized 
controlled trial has shown motivational interviewing 
focused on overdose risk reduction to be superior to 
usual care in reducing self-reported opioid overdose 
risk behaviors in patients presenting to the emergency 
department with non-medical use of prescription opioids 
[11]. This is promising evidence that non-judgmental, 
goal directed interviewing can reduce risky behaviors in 
patients using opioids non-medically. Future studies will 
be needed to evaluate outcomes in other at risk groups 
for opioid overdose as well as whether including nalox-
one education and distribution may amplify reductions 
in risk taking behaviors.
Equipped with the education and training provided 
by OEND programs, naloxone can be administered by 
bystanders, whether that bystander is a person who also 
uses opioids, a friend, family member, acquaintance or 
first responder, such as police or firefighter personnel 
[12]. In some communities, people who use opioids and 
their social networks can obtain training and naloxone 
rescue kits at many different venues including needle-
syringe access programs, inpatient and outpatient addic-
tion treatment programs [9], primary care [13], and 
support group meetings [14]. It is important to recognize 
periods of abstinence resulting in loss of opioid tolerance, 
such as post-incarceration [15, 16] or after completing 
varying types of addiction treatment [17], as a high-risk 
time for an overdose event if relapse occurs. Therefore, 
providing OEND to opioid users and their social net-
works while they are engaged in addiction treatment, 
general health care, or the criminal justice system is criti-
cally important [18].
The legal framework in most states has shifted to pro-
mote access to naloxone kits by allowing health pro-
fessionals to prescribe naloxone to third-party family 
members as well as making naloxone available without 
a prescription at retail pharmacies via a standing, often 
state-wide, prescription [19]. While community based 
naloxone programs remain the most common driver for 
naloxone distribution [9], naloxone prescriptions dis-
pensed at US retail pharmacies have risen steeply since 
2013 [20]. Retail pharmacy distribution is a promising 
way to improve access to naloxone, especially in rural 
areas which may be underserved by community OEND 
programs.
A mortality benefit from OEND is supported by observa-
tional evidence including an interrupted time series study 
that showed Massachusetts communities with OEND had 
reduced opioid overdose death rates compared to commu-
nities that did not have OEND [21] and a pre-post study 
in Scotland showed a reduction in overdose death rates 
among people released from prison [22]. A modeling study 
has demonstrated OEND to be cost effective for people 
who use heroin [23]. A trial published in 2016 found that 
co-prescribing naloxone rescue kits to patients treated 
with opioids for chronic pain in primary care resulted in 
reduced opioid-related emergency department visits [13]. 
This evidence in the context of an opioid overdose crisis 
is compelling for improving access to OEND; however, 
important questions remain unanswered.
What we don’t know
Who should receive opioid overdose education 
and naloxone rescue kits?
Existing evidence has focused primarily on training 
and delivering naloxone kits to people who use heroin 
(PWUH) via community based programs. This approach 
has proved fruitful, likely because PWUH are apt to use 
with others and/or be a bystander for another’s overdose. 
Thus, PWUH may be receptive to OEND intervention 
because they understand via their own experience the 
risks associated with opioid use and may be more likely 
to be present at an overdose event. It is not known if tar-
geting OEND to friends, family members, acquaintances 
of opioid users, or the public could reduce mortality 
beyond the benefits of targeting OEND to PWUH.
Prescribers and pharmacists need guidance on who 
should receive naloxone rescue kits. One approach is to 
develop an overdose risk tool to help deliver OEND to 
people at risk for overdose. However, OEND should tar-
get people most likely to witness another’s overdose, in 
addition to focusing on individuals who are at risk them-
selves. Therefore, providing OEND to the social networks 
of those identified to be high risk for overdose might be 
especially efficient. Importantly, the social networks of 
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people who use opioids may not be interacting with com-
munity based OEND programs or health care personnel 
may not be identifying them as potential beneficiaries of 
OEND.
Should all patients receiving opioid therapy be offered 
naloxone co‑prescribing?
Center for Disease Control and Prevention opioid pre-
scribing guidelines released in 2016 recommend consid-
ering naloxone and overdose prevention education for 
patients and household members of patients prescribed 
opioids with a history of overdose, history of substance use 
disorder, higher opioid dosages (≥50 MME/day), or con-
current benzodiazepine use [24]. A study of co-prescribing 
naloxone as a universal precaution to patients on chronic 
opioid therapy for non-cancer related pain demonstrated 
reduced opioid-related emergency department visits after 
substantial, but not universal, uptake by prescribers and 
patients at a group of community health centers [13]. 
The patients who actually received naloxone rescue kits 
in this study were more likely to be those on higher doses 
of opioids and with previous opioid-related emergency 
department visits. How best to work with patients, their 
household members, prescribers, and pharmacies to get 
naloxone kits to a broader group of people exposed to opi-
oids and at risk for overdose warrants further intervention 
development and implementation studies.
Does OEND alter opioid prescribing practices?
The few studies that have examined how OEND may 
impact prescribing practices are mixed, and point to 
a nuanced relationship between offering naloxone to 
patients treated with prescription opioids. A qualitative 
study found that prescribers were conflicted about co-
prescribing an opioid and an opioid antagonist [25]. Some 
providers interviewed for this study questioned whether 
opioids were contraindicated if naloxone co-prescribing 
was being considered. Whereas, some felt that the process 
of OEND alone might improve conversations about the 
risks of opioids. Providers felt that discussing and address-
ing overdose risk with OEND might reduce patients’ risk 
taking behaviors [25]. The previously mentioned study of 
co-prescribing as an intervention for patients on long-
term opioids for chronic pain found reduced opioid-
related emergency department visits, but prescribing 
naloxone had no net effect on the prescribed opioid dose 
[13]. A better understanding of how OEND and prescrib-
ing affect one another will require further study.
How should the perception of risk compensation be 
addressed?
Some opioid prescribers [25] and policymakers [26] are 
concerned about “risk compensation,” meaning that 
having a naloxone rescue kit may increase risky opioid 
use. Well-designed observational studies have shown 
reductions in community level opioid overdose death 
rates where OEND has been implemented [21, 22], and 
reduced opioid-related emergency department visits 
among chronic pain patients who were co-prescribed 
naloxone rescue kits [13]. Thus, if there is any substan-
tial increase in risky behavior due to risk compensation, 
it is outweighed by the important benefits of OEND. The 
concern about risk compensation is similar to other key 
public health interventions, such as seat belts to pre-
vent motor vehicle deaths, vaccination and condoms 
to prevent sexually transmitted infections, and needle-
syringe programs to prevent infectious disease trans-
mission. Studies that have looked for risk compensation 
from naloxone access among people who use heroin, 
have found no clear evidence of it [27, 28]. This is likely 
because people who use opioids are very averse to nalox-
one induced opioid withdrawal, and opioid overdose 
education may reduce incremental risky behaviors. How-
ever, the perception of risk compensation is an important 
barrier to wider implementation of OEND. Therefore, 
implementation studies that address the perception of 
risk compensation among prescribers and minimize 
any increases in overdose risk behaviors resulting from 
OEND are warranted.
How should naloxone be administered and at what dose?
Naloxone formulations and delivery systems
There are now four different formulations of naloxone 
that are used in naloxone rescue kits: (1) injectable nalox-
one that is drawn up out of a vial with a needle into a 
syringe with a dose concentration of 0.4 mg/1 ml, (2) an 
auto injector with audio prompts that administers a 
0.4 mg intramuscular dose via a retractable needle, (3) a 
single-step nasal spray that administers a dose concentra-
tion of 4 mg/0.1 mL into one nostril, and (4) a multi-step 
nasal spray assembled by combining a pre-filled luer lock 
syringe with a nasal atomizer, that administers a dose 
concentration of 2 mg/2 ml, where 1 ml is administered 
to each nostril.1 OEND programs have favored syringe 
and vial intramuscular naloxone and multi-step nasal 
naloxone because of lower cost and early availability. 
Naloxone kits, regardless of formulation, generally 
include two doses, so that if the first dose does not result 
in spontaneous respirations, then a second dose may be 
administered.
Intranasal delivery has several potential benefits. First, 
no injection is required which facilitates layperson use 
1 Nasal naloxone delivered via syringe and nasal atomizer as 2 mg/2 ml is 
not FDA approved.
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because there is no fear nor risk of needle stick injury. 
Furthermore, the administration of a nasal spray requires 
less training than the administration of an injection, and 
the nose is typically readily accessible for administration. 
The new FDA-approved single-step nasal device does 
not require assembly providing a potential time saving 
advantage over the multi-step device. In 2016, informa-
tion about how the single-step device is used in actual 
overdose events in people with opioid tolerance is lack-
ing. Little is known about how active nasal naloxone is 
at opioid receptors in real world circumstances and how 
reproducible this method of delivery is.
The IM auto-injector also has benefits. The product was 
designed such that a layperson could easily and quickly 
administer naloxone via a one-piece device that instructs 
rescuers step-by-step, in real time through the process of 
delivering intramuscular naloxone. In addition to provid-
ing audible instruction, the device protects the needle 
via a plastic housing, thereby reducing unintended nee-
dle exposure. The cost of the auto-injector has been high 
and insurance coverage variable. Both cost and variable 
insurance coverage are important barriers to naloxone 
access. More information about real-life use of naloxone 
is needed to understand if this technology improves the 
correct and timely delivery of naloxone.
Some providers and health care systems may favor 
prescribing the single-step nasal device or the IM auto-
injector because these devices are designed and FDA 
approved for bystander administration. OEND programs 
have favored the multi-step nasal device or intramuscu-
lar naloxone because the FDA approved devices are more 
expensive. It remains to be seen how the new, higher 
cost, FDA approved devices alter access to naloxone and 
potentially health outcomes.
Dosing
The most common and clinically important adverse 
effect of naloxone is precipitated opioid withdrawal. 
Ideally the dose of naloxone would be large enough to 
successfully reverse respiratory depression, yet small 
enough to avoid opioid withdrawal. It is not well known 
whether the dose of naloxone currently being utilized 
optimally balances the lifesaving properties of naloxone 
with risk of inducing withdrawal. The newer one-step 
nasal spray delivers naloxone at higher concentration 
and larger dose compared to intramuscular delivery 
of 0.4  mg/1  ml naloxone in healthy volunteers. It is 
expected, but not yet proven, that the one-step device 
will result in more successful reversals of respiratory 
depression compared to other delivery devices. How-
ever, it is also anticipated that naloxone induced with-
drawal symptoms will be more frequent and possibly 
more severe because a higher dose of naloxone is used 
in this device. The trade-off between high doses of 
naloxone to prevent overdoses that fail to reverse with 
naloxone and the increased risk of withdrawal gener-
ally favors giving higher dose naloxone to help save 
lives. However, we do not yet know if naloxone induced 
withdrawal results in greater risk of repeat opioid use 
and recurrent overdose. In addition, it is reasonable 
to expect that locales with higher potency heroin and/
or greater use of fentanyl or fentanyl derivatives would 
benefit more from higher dose naloxone. Thus, commu-
nities with more high potency opioid use may be more 
inclined to adopt higher dose naloxone kits, and accept 
the potential for more frequent and severe opioid with-
drawal. More information about the frequency of opioid 
overdoses not responding to naloxone as well as a better 
understanding of what happens to patients after receiv-
ing naloxone, especially those who experience induced 
withdrawal, will help inform decisions regarding nalox-
one dosing.
What happens after overdose rescue with naloxone 
to keep people safe?
Due to the neurobehavioral adaptations that occur 
among people who have an opioid use disorder, overdose 
survivors are unlikely to seek and engage wholeheartedly 
in addiction treatment immediately after receiving nalox-
one. Most survivors will be experiencing precipitated 
withdrawal from naloxone and will be having intense 
cravings to use opioids. Treating a survivor in withdrawal 
with a daily long-acting opioid agonist, like methadone 
or buprenorphine, is the most promising way to work 
towards engaging him or her in treatment and the best 
way to keep him or her safe from using more unsuper-
vised opioids. Initiation of buprenorphine/naloxone in 
the emergency department (ED) has been evaluated 
in a randomized clinical trial of 329 opioid-dependent 
patients, of which 8.8% presented to the ED with an 
overdose event. This study demonstrated that initia-
tion of buprenorphine/naloxone treatment in the emer-
gency department with referral to further care resulted in 
improved engagement in medical care, less self-reported 
opioid use and less utilization of inpatient services at 
30 days compared to referral to outpatient treatment or 
brief intervention [29]. This study is promising evidence, 
in a small number of patients at one academic medical 
center, that immediate initiation of agonist therapy may 
improve outcomes. This study did not report on out-
comes in the subset of participants who required nalox-
one. Offering agonist therapy immediately after overdose 
requiring naloxone, whether the person experienced 
naloxone induced withdrawal or not, is an important 
area of future research to improve care after an overdose 
event.
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Some have called for mandated treatment after an 
overdose, which has unclear efficacy as well as ethical 
and civil rights implications [30]. Other potential inter-
ventions include survivor-centered harm reduction and 
treatment outreach to people who have overdosed and 
their social networks. The Anchor Recovery Coach Pro-
gram in Rhode Island provides on-call recovery coaches 
to survivors presenting to the emergency department 
[31]. When the survivor has a disease that involves using 
opioids despite adverse consequences, engaging others in 
the survivor’s social network to promote overdose pre-
vention strategies and support seeking treatment may 
reduce the likelihood of the next overdose. Programs 
providing care, counseling, and OEND immediately after 
an overdose to survivors and their social networks may 
provide a unique opportunity to reduce repeat opioid 
overdose and encourage engagement in further care, and 
therefore need to be evaluated.
What are the subacute effects of non‑fatal opioid overdose 
and how can they be treated or prevented?
Complications from non-fatal overdose include but are 
not limited to: aspiration, anoxic brain injury, nerve pal-
sies, and trauma related injuries. The incidence of these 
complications has not been well described. Addition-
ally, it is not known how long and in what setting people 
should be monitored after naloxone rescue to reduce the 
risks of overdose complications.
What kind of training should be provided with naloxone 
distribution?
In many communities, laypersons can obtain naloxone 
at different locations which provide varied informa-
tion about overdose and naloxone. This education dif-
fers across several potentially important variables which 
could alter the impact of OEND programs. First, the 
material may be conveyed in multiple formats. Com-
monly utilized techniques include: didactic education, 
hand-out media such as pamphlets, and/or media like 
video that is consumed while at the training session. 
Some programs utilize hands-on training via a demo 
device, while in some locations this may not be avail-
able. Second, who delivers the content and for how long 
is not standardized. In some places, trained community 
members provide instruction while in more formal medi-
cal settings, physicians, nurses, or pharmacists may lead 
overdose education and naloxone training. Third, the 
length of OEND training also fluctuates between set-
tings, trainers, and trainees. Space, trainer time, and 
trainee time may be limited and trainee knowledge and 
cognition may require different training intensity. Further 
study into how best to educate laypersons about overdose 
and naloxone is needed to optimize the effectiveness 
and efficiency of OEND. Standardization of the core 
elements of OEND training, yet allowing for some flex-
ibility of other elements of the training, will help ensure 
the future rescuer achieves a minimum competency and 
comfort level with naloxone. Standardizing and tailoring 
OEND curriculum will need to evolve as more naloxone 
devices with various concentrations, doses, and delivery 
mechanisms become available to wider groups of poten-
tial rescuers.
The American Heart Association (AHA), in its most 
recent update in November 2015, incorporated nalox-
one into its emergency response algorithms [32]. This 
presents a new opportunity for opioid overdose educa-
tion and naloxone training to occur along with AHA 
emergency response trainings. While OEND can be 
incorporated into AHA trainings, it is not known if more 
advanced resuscitation skills, such as chest compres-
sions and automatic defibrillator use should be provided 
at existing OEND programs. These additional skills may 
be useful in opioid overdose rescues, however teaching 
these skills may result in additional barriers to naloxone 
access in the community. AHA cardiopulmonary resus-
citation course includes proficiency testing prior to cer-
tification and requires a refresher course every 2 years to 
maintain certification. It is not known whether testing 
proficiency or requiring recertification might improve 
overdose related clinical outcomes.
After recognizing an overdose, what is the correct order 
of actions?
OEND programs and the AHA instruct rescuers to 
call for help, start ventilation or CPR, deliver naloxone, 
remain with the person until help arrives, and place vic-
tim in the rescue position. OEND programs, naloxone 
package inserts, the World Health Organization and the 
AHA have various recommendations regarding the spe-
cific order in which these key steps should be performed. 
It is not known if or how the order of these rescue steps 
could alter clinical outcomes. Further study will hopefully 
standardize how we respond to opioid overdose events.
How do local and state laws affect OEND?
The legal framework in which OEND programs oper-
ate may have significant implications for how effectively 
naloxone reduces overdose deaths. OEND programs exist 
in different state and local legal environments. Many 
states have attempted to limit civil or criminal liabilities 
for responding to an overdose, as well as administering, 
prescribing or distributing naloxone. These laws differ by 
location but generally encourage wider access to OEND 
and help encourage rescuers to call for emergency ser-
vices by reducing fears of legal repercussions when first-
responders, including police, arrive. Currently, we do not 
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know how OEND effects a rescuer’s decision to call for 
emergency help. OEND programs recommend calling for 
emergency services, but rescues are occurring without 
summoning professional help. This may be due to fear of 
legal consequences to either the overdose survivor or the 
rescuer, but other less well known factors may also dis-
courage calling for help. The implications of layperson 
rescue without the survivor interacting with professional 
help after this event are not known. It would be informa-
tive to compare effectiveness and distribution of naloxone 
in areas that have different legal protections and evaluate 
how OEND effects professional help seeking after over-
dose to understand and address potential barriers to 
naloxone use.
Would dedicated CME training programs for prescribers 
improve naloxone prescribing and distribution?
Most clinicians experience with naloxone occurs in a 
hospital or pre-hospital setting where the antidote is 
delivered by nurses or first responders. Relatively little is 
known about prescribers’ knowledge about naloxone for 
community use by lay bystanders. Improving prescriber 
knowledge about community naloxone programs and 
prescribing naloxone via pharmacies may help distribute 
naloxone more broadly, especially in communities that 
do not have access to an OEND program.
What are validated research and clinical measures 
of overdose and overdose risk behaviors?
We have called for additional research to improve the 
clinical and health system benefits of OEND. High qual-
ity research relies on well-defined clinical events and 
outcomes as well as validated measures. Fatal opioid 
overdoses are defined typically via cause of death fields 
on death certificates, which are available in all communi-
ties. However, standardization of what constitutes a fatal 
overdose event is needed to help facilitate research across 
jurisdictions and improve epidemiologic reporting. Addi-
tionally, there are not validated definitions of non-fatal 
opioid overdose, whether measured by self-report, clini-
cal, or administrative data. For opioid overdose, the basic 
components are exposure to an opioid that results in 
unresponsiveness and respiratory depression. Definitions 
of overdose which require that help was sought or that 
naloxone was administered likely increase specificity, but 
sacrifice sensitivity. Opioid overdose rescues may occur 
without calling for help and/or administering naloxone. 
If the definition of non-fatal overdoses requires these ele-
ments, it is likely that some non-fatal opioid overdoses 
would not be classified appropriately, therefore reducing 
sensitivity. On the other hand, a firm definition of non-
fatal opioid overdose will be needed to exclude other 
causes of unresponsiveness and/or respiratory depression 
to improve specificity. Universally accepted definitions of 
both fatal and non-fatal opioid overdose events will be 
needed to help improve OEND research in the future.
Overdose risk behaviors have been well described. 
Assessing overdose risk and educating patients about it 
are key elements of overdose prevention. We have yet 
to develop a validated, widely applicable overdose risk 
measure that is useful clinically or for research.
Conclusion
The opioid use and overdose crisis is persistent and 
dynamic, garnering much attention from the public, 
policymakers and public health officials. In an effort 
to curb opioid related overdoses and deaths the federal 
government has prioritized increasing prescriber educa-
tion, improving access to treatments for opioid use dis-
order and naloxone. As an antidote to opioid overdoses, 
naloxone has proven to be a valuable tool in combating 
overdose deaths and associated morbidity. Further inves-
tigation into important knowledge gaps will help unlock 
the potential of naloxone needed to address the pervasive 
opioid overdose crisis.
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